{"id":"https://openalex.org/W4415939877","doi":"https://doi.org/10.1016/j.annonc.2025.08.2276","title":"1648P Evaluating curative potential of lifileucel in previously treated advanced melanoma: Analyses from C-144-01 trial","display_name":"1648P Evaluating curative potential of lifileucel in previously treated advanced melanoma: Analyses from C-144-01 trial","publication_year":2025,"publication_date":"2025-09-01","ids":{"openalex":"https://openalex.org/W4415939877","doi":"https://doi.org/10.1016/j.annonc.2025.08.2276"},"language":"en","primary_location":{"id":"doi:10.1016/j.annonc.2025.08.2276","doi":"https://doi.org/10.1016/j.annonc.2025.08.2276","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2025.08.2276","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.annonc.2025.08.2276","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076054848","display_name":"James Larkin","orcid":"https://orcid.org/0000-0001-5569-9523","observed_orcids":["https://orcid.org/0000-0001-5569-9523"]},"institutions":[{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"J. Larkin","raw_affiliation_strings":["Medicine Department, The Royal Marsden Hospital - Chelsea, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine Department, The Royal Marsden Hospital - Chelsea, London, United Kingdom","institution_ids":["https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069095893","display_name":"Paul C. Lorigan","orcid":"https://orcid.org/0000-0002-8875-2164","observed_orcids":["https://orcid.org/0000-0002-8875-2164"]},"institutions":[{"id":"https://openalex.org/I4210131968","display_name":"The Christie Hospital","ror":"https://ror.org/03nd63441","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"P. Lorigan","raw_affiliation_strings":["Medical Oncology Dept., The Christie NHS Foundation Trust, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Dept., The Christie NHS Foundation Trust, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4210131968","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015954259","display_name":"E. Dlotko","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Dlotko","raw_affiliation_strings":["Health Economics and Outcomes Research, Access, FIECON Limited, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research, Access, FIECON Limited, London, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101459706","display_name":"Murat Kurt","orcid":"https://orcid.org/0009-0008-9496-6215","observed_orcids":["https://orcid.org/0009-0008-9496-6215"]},"institutions":[{"id":"https://openalex.org/I4405272808","display_name":"Iovance Biotherapeutics (United States)","ror":"https://ror.org/04rbqb740","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272808"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M. Kurt","raw_affiliation_strings":["Global Health Economics & Outcomes Research, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Health Economics & Outcomes Research, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America","institution_ids":["https://openalex.org/I4405272808"]}]},{"author_position":"middle","author":{"id":null,"display_name":"L. Cox","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L. Cox","raw_affiliation_strings":["Health Economics & Outcomes Research, Access, Fiecon Limited, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics & Outcomes Research, Access, Fiecon Limited, London, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029950273","display_name":"Donata Freigofaite","orcid":"https://orcid.org/0009-0000-9188-6385","observed_orcids":["https://orcid.org/0009-0000-9188-6385"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Freigofaite","raw_affiliation_strings":["Health Economics and Outcomes Research, Access, FIECON Limited, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Health Economics and Outcomes Research, Access, FIECON Limited, London, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100378537","display_name":"Jing Wang","orcid":"https://orcid.org/0000-0002-5398-0802","observed_orcids":["https://orcid.org/0000-0002-5398-0802","https://orcid.org/0000-0001-5412-9860"]},"institutions":[{"id":"https://openalex.org/I4405272808","display_name":"Iovance Biotherapeutics (United States)","ror":"https://ror.org/04rbqb740","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272808"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Wang","raw_affiliation_strings":["Global Patient Operations, Value and Access, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Patient Operations, Value and Access, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America","institution_ids":["https://openalex.org/I4405272808"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Jiang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405272808","display_name":"Iovance Biotherapeutics (United States)","ror":"https://ror.org/04rbqb740","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272808"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Jiang","raw_affiliation_strings":["Global Patient Operations, Value and Access, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Patient Operations, Value and Access, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America","institution_ids":["https://openalex.org/I4405272808"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040197625","display_name":"Xing Wu","orcid":"https://orcid.org/0000-0003-3506-5544","observed_orcids":["https://orcid.org/0000-0003-3506-5544","https://orcid.org/0009-0006-7674-8471"]},"institutions":[{"id":"https://openalex.org/I4405272808","display_name":"Iovance Biotherapeutics (United States)","ror":"https://ror.org/04rbqb740","country_code":"US","type":"company","lineage":["https://openalex.org/I4405272808"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"X. Wu","raw_affiliation_strings":["Biostatistics, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biostatistics, Iovance Biotherapeutics, Inc. - Headquarters, San Carlos, United States of America","institution_ids":["https://openalex.org/I4405272808"]}]},{"author_position":"last","author":{"id":null,"display_name":"P. Mohr","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210138735","display_name":"Elbe Kliniken Stade-Buxtehude","ror":"https://ror.org/04psvb108","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210138735"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"P. Mohr","raw_affiliation_strings":["Dermato-Oncology Department, Dermatologic Center Buxtehude, Buxtehude, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermato-Oncology Department, Dermatologic Center Buxtehude, Buxtehude, Germany","institution_ids":["https://openalex.org/I4210138735"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5080,"currency":"USD","value_usd":5080},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.31713868,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":null,"first_page":"S914","last_page":"S914"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7060999870300293,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.7060999870300293,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.16539999842643738,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.04879999905824661,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lifileucel","display_name":"lifileucel","score":1.0},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7609999775886536},{"id":"https://openalex.org/keywords/long-term-survivors","display_name":"long-term survivors","score":0.8510000109672546},{"id":"https://openalex.org/keywords/cell-therapy","display_name":"cell therapy","score":0.6340000033378601},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7269999980926514}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.965399980545044},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6553000211715698},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6367999911308289},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5307999849319458},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.5212000012397766},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5141000151634216},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.48660001158714294},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4693000018596649},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.42170000076293945},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3919999897480011},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.37220001220703125},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3573000133037567},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.34439998865127563},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.3255000114440918},{"id":"https://openalex.org/C2777761686","wikidata":"https://www.wikidata.org/wiki/Q715347","display_name":"Lymphocyte","level":2,"score":0.3000999987125397},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.2912999987602234},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2870999872684479},{"id":"https://openalex.org/C2993769353","wikidata":"https://www.wikidata.org/wiki/Q7598360","display_name":"Standard of care","level":2,"score":0.28529998660087585},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.27559998631477356}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.annonc.2025.08.2276","doi":"https://doi.org/10.1016/j.annonc.2025.08.2276","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2025.08.2276","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.annonc.2025.08.2276","doi":"https://doi.org/10.1016/j.annonc.2025.08.2276","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.annonc.2025.08.2276","pdf_url":null,"source":{"id":"https://openalex.org/S41454044","display_name":"Annals of Oncology","issn_l":"0923-7534","issn":["0923-7534","1569-8041"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7162506202","https://openalex.org/W4389480820","https://openalex.org/W4410818663","https://openalex.org/W4410961146","https://openalex.org/W4388080906","https://openalex.org/W3176386559","https://openalex.org/W4387811025","https://openalex.org/W4311310504","https://openalex.org/W3028793019","https://openalex.org/W4308402895"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2025-11-06T00:00:00"}